Ticker

Analyst Price Targets — FULC

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
June 2, 2026 10:06 amAndrew FeinH.C. Wainwright$3.00$6.42TheFly Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
June 2, 2026 10:03 am—Jefferies$4.00$6.42StreetInsider Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform
June 2, 2026 10:02 am—Leerink Partners$4.00$6.42TheFly Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink
June 2, 2026 5:04 amGregory RenzaTruist Financial$4.00$6.42StreetInsider Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold
June 2, 2026 12:30 am—Piper Sandler$3.00$6.42TheFly Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler
February 24, 2026 6:38 pmGregory RenzaTruist Financial$17.00$8.96TheFly Fulcrum Therapeutics price target lowered to $17 from $18 at Truist
December 11, 2025 2:04 pm—Truist Financial$18.00$12.65TheFly Fulcrum Therapeutics price target raised to $18 from $14 at Truist
December 8, 2025 2:04 pm—Stifel Nicolaus$25.00$14.07TheFly Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
December 8, 2025 1:42 pmKristen KluskaCantor Fitzgerald$24.00$13.74TheFly Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
December 8, 2025 1:18 pm—RBC Capital$10.00$14.06TheFly Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital

Latest News for FULC

Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (FULC) of a Securities Law Investigation

New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum…

Newsfile Corp • Aug 31, 2026
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Contact the Firm Regarding a Securities Investigation

New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum…

Newsfile Corp • Aug 28, 2026
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to a Securities Law Investigation

New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum…

Newsfile Corp • Aug 26, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire • Aug 24, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for FULC.

No House trades found for FULC.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top